Giuseppe Claudio VISCOMI,Paola MAFFEI,Giuseppe BOTTONI,Maria GRIMALDI
申请号:
US15130324
公开号:
US20170071916A1
申请日:
2016.04.15
申请国别(地区):
US
年份:
2017
代理人:
摘要:
Disclosed herein are methods of treating a patient having an intestinal disorder, the methods comprising: administering to a patient in need thereof a pharmaceutical composition comprising a hydrate or solvate form of rifaximin in polymorphic form β, alone or in a mixture with other crystalline, hydrate, solvate or amorphous forms of rifaximin, in gastroresistant microgranules, wherein the rifaximin is administered at a dose of at least 800 mg per day for a period of at least 7 days.